1. GPCR/G Protein Neuronal Signaling
  2. 5-HT Receptor
  3. SEP-363856

SEP-363856  (Synonyms: SEP-856)

目录号: HY-136109A
产品使用指南

SEP-363856 (SEP-856) 是具有口服活性的 TAAR15-HT1A 激动剂、中枢神经系统活性的抗精神病活性化合物,具有研究精神分裂症的潜力。

该游离形式化合物不稳定,推荐具有相同生物学活性的稳定盐形式 SEP-363856 hydrochloride

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

SEP-363856 Chemical Structure

SEP-363856 Chemical Structure

CAS No. : 1310426-33-5

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

SEP-363856 的其他形式现货产品:

Customer Review

Other Forms of SEP-363856:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

SEP-363856 (SEP-856), an orally active TAAR1 and 5-HT1A agonist and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects. SEP-363856 (SEP-856) has the potential for the study of schizophrenia[1].

IC50 & Target[1]

TAAR1

0.140 μM (EC50)

5-HT1A Receptor

2.3 μM (EC50)

5-HT1B Receptor

15.6 μM (EC50)

5-HT1D Receptor

0.262 μM (EC50)

5-HT2A Receptor

>10 μM (EC50)

5-HT2C Receptor

30 μM (EC50)

5-HT7 Receptor

6.7 μM (EC50)

体外研究
(In Vitro)

SEP-363856 (10 μM) 对 α2A、α2B、D2、5-HT1A、5-HT1B、5-HT1D、5-HT2A、5-HT2B、5-HT2C 和 5-HT7 受体的特异性结合抑制率 >50%[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

SEP-363856(0.3、1 和 10 mg/kg,腹腔注射)具有中枢神经活性,表现出与已知抗精神病药物类似的行为特征[1]
SEP-363856(0.3、1 和 10 mg/kg,口服一次)可显著降低 PCP 引起的多动症[1]
口服 SEP-363856(1、3 和 10 mg/kg)可导致剂量依赖性的 REM 睡眠减少、REM 睡眠潜伏期增加和累积清醒 (W) 时间增加[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Acute treatment with phencyclidine (PCP), which induces robust hyperactivity in rodents[1].
Dosage: 0.3, 1 and 3 mg/kg.
Administration: Orally once.
Result: Resulted in a dose-dependent inhibition of PCP-induced hyperactivity responses in C57Bl/6J mice (1-way ANOVA F (5, 59) = 18.96, p < 0.0001; Tukey’s post-hoc test, p < 0.05) with a 50% effective dose (ED50) of approximately 0.3 mg/kg.
Animal Model: Male Sprague Dawley rats[1].
Dosage: 1, 2, and 5 mg/kg.
Administration: I.V. injection. (Pharmacokinetic Analysis).
Result: 0.5 hours in mice and rats and maximum plasma concentrations reached within 6 ± 2.83 hours in monkeys.
Penetrated mouse and rat brains after oral administration (10 mg/kg), with average brain-to-plasma AUC ratios of ~3 respectively.
Clinical Trial
分子量

183.27

Formula

C9H13NOS

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
SEP-363856
目录号:
HY-136109A
需求量: